The global hydrogel-based drug delivery system market size is anticipated to reach USD 11.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2024 to 2030. Hydrogels help in achieving spatial and temporal control over the release of the incorporated drug. Therefore, the surging demand for controlled releases drug delivery system across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.

Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

Access the Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route, By Region, And Segment Forecast, 2024 - 2030

The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.

There are numerous clinical studies underway specific to hydrogel-based drug delivery systems and various hydrogel technologies have already received regulatory approval for biomedical application. However, the technological challenges including the absence of defined regulatory guidelines, chemistry, complex manufacturing and control paraments, and practical adaptability are major roadblocks in the successful implementation in drug delivery use. For instance, the fabrication of hydrogel is complex and varies significantly depending upon the hydrogel systems.

Hydrogel-based Drug Delivery System Market Report Highlights

·        Based on polymer origin, the synthetic segment held the largest proportion of market share in 2023

·        The hybrid segment is expected to witness the fastest growth rate over the forecast period owing to the development of stimuli-responsive hydrogel technology

·        The synthetic segment is anticipated to grow fast over the forecast period compared to natural hydrogels due to their high drug loading capacity and improved mechanical strength

·        Based on delivery route, the ocular segment accounted for the largest revenue share in 2023

·        The subcutaneous segment is expected to grow at a healthy rate over the forecast period owing to the increasing number of clinical and pre-clinical studies carried out

·        North America holds the largest revenue share in this market due to the presence of key companies in the region doing R&D on specific hydrogel-based drug delivery systems

·        In Asia Pacific, the market is expected to grow at the fastest rate over the forecast period due to large patient base, improving healthcare infrastructure, and surging demand for modern therapies

Order your free sample copy of “Hydrogel-based Drug Delivery System Market Report 2024 - 2030, published by Grand View Research

Key Hydrogel-based Drug Based Delivery System Company Insights

Some key companies in the market include GALDERMA; Blairex Laboratories, Inc.; Johnson & Johnson; Bausch + Lomb; Medtronic; and Ocular Therapeutix, Inc. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other emerging and prominent industry participants.

·        Ocular Therapeutix, Inc., is a biopharmaceutical company that specializes in creating, advancing, and marketing new treatments for eye disorders. It employs its own bioresorbable hydrogel-based formulation technology, ELUTYX. The company has manufacturing facilities in Massachusetts.

·        Blairex Laboratories, Inc., a global pharmaceutical company, delivers products related to the consumer and pharmaceutical industry. Some of the company's major offerings are sterile saline solutions and contact lens care.

Key Hydrogel-based Drug Delivery System Companies:

The following are the leading companies in the hydrogel-based drug delivery system market. These companies collectively hold the largest market share and dictate industry trends.

·        GALDERMA

·        Blairex Laboratories, Inc

·        Johnson & Johnson

·        Bausch + Lomb.

·        Medtronic

·        Ocular Therapeutix, Inc.

·        Ferring B.V.

·        Endo, Inc.

·        Tolmar Inc

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email:  sales@grandviewresearch.com